Additive value of [ 18 F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome.

Autor: Katzdobler S; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany., Nitschmann A; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany., Barthel H; Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany., Bischof G; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.; Molecular Organization of the Brain, Institute for Neuroscience and Medicine, INM-2), Jülich, Germany., Beyer L; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany., Marek K; InviCRO, LLC, Boston, MA, USA.; Molecular Neuroimaging, A Division of inviCRO, New Haven, CT, USA., Song M; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany., Wagemann O; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany., Palleis C; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany., Weidinger E; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany., Nack A; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany., Fietzek U; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany., Kurz C; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany., Häckert J; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany., Stapf T; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany., Ferschmann C; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany., Scheifele M; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany., Eckenweber F; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany., Biechele G; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany., Franzmeier N; Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany., Dewenter A; Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany., Schönecker S; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany., Saur D; Department of Neurology, University of Leipzig Medical Center, Leipzig, Germany., Schroeter ML; Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany.; LIFE - Leipzig Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany.; Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany., Rumpf JJ; Department of Neurology, University of Leipzig Medical Center, Leipzig, Germany., Rullmann M; Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany., Schildan A; Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany., Patt M; Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany., Stephens AW; Life Molecular Imaging GmbH, Berlin, Germany., van Eimeren T; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany., Neumaier B; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.; Institute for Neuroscience and Medicine (INM-3), Cognitive Neuroscience, Research Centre Juelich, Juelich, Germany., Drzezga A; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.; Molecular Organization of the Brain, Institute for Neuroscience and Medicine, INM-2), Jülich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany., Danek A; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany., Classen J; Department of Neurology, University of Leipzig Medical Center, Leipzig, Germany., Bürger K; Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany., Janowitz D; Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany., Rauchmann BS; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany.; Department of Radiology, University Hospital of Munich, LMU Munich, Munich, Germany., Stöcklein S; Department of Radiology, University Hospital of Munich, LMU Munich, Munich, Germany., Perneczky R; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.; Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany.; Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College, London, UK., Schöberl F; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany., Zwergal A; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany., Höglinger GU; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.; Department of Neurology, Hannover Medical School, Hannover, Germany., Bartenstein P; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany., Villemagne V; Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia.; Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia.; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA., Seibyl J; InviCRO, LLC, Boston, MA, USA.; Molecular Neuroimaging, A Division of inviCRO, New Haven, CT, USA., Sabri O; Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany., Levin J; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany., Brendel M; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. matthias.brendel@med.uni-muenchen.de.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. matthias.brendel@med.uni-muenchen.de.; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany. matthias.brendel@med.uni-muenchen.de.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2023 Jan; Vol. 50 (2), pp. 423-434. Date of Electronic Publication: 2022 Sep 14.
DOI: 10.1007/s00259-022-05964-w
Abstrakt: Purpose: Early after [ 18 F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [ 18 F]PI-2620 tau-PET is able to discriminate the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome (4RTs) from disease controls and healthy controls. Here, we investigated whether early-phase [ 18 F]PI-2620 PET has an additive value for biomarker based evaluation of 4RTs.
Methods: Seventy-eight patients with 4RTs (71 ± 7 years, 39 female), 79 patients with other neurodegenerative diseases (67 ± 12 years, 35 female) and twelve age-matched controls (69 ± 8 years, 8 female) underwent dynamic (0-60 min) [ 18 F]PI-2620 PET imaging. Regional perfusion (0.5-2.5 min p.i.) and tau load (20-40 min p.i.) were measured in 246 predefined brain regions [standardized-uptake-value ratios (SUVr), cerebellar reference]. Regional SUVr were compared between 4RTs and controls by an ANOVA including false-discovery-rate (FDR, p < 0.01) correction. Hypoperfusion in resulting 4RT target regions was evaluated at the patient level in all patients (mean value - 2SD threshold). Additionally, perfusion and tau pattern expression levels were explored regarding their potential discriminatory value of 4RTs against other neurodegenerative disorders, including validation in an independent external dataset (n = 37), and correlated with clinical severity in 4RTs (PSP rating scale, MoCA, activities of daily living).
Results: Patients with 4RTs had significant hypoperfusion in 21/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (R = 0.402; p = 0.0012) and activities of daily living (R =  - 0.431; p = 0.0005).
Conclusion: [ 18 F]PI-2620 perfusion imaging mirrors known topology of regional hypoperfusion in 4RTs. Single region hypoperfusion is not specific for 4RTs, but perfusion pattern expression may provide an additive value for the discrimination of 4RTs from other neurodegenerative diseases and correlates closer with clinical severity than tau pattern expression.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje